INS1148 / Opsidio, AbbVie, Insmed - LARVOL DELTA

Insmed Provides…Business Update (PRNewswire) - "Insmed also announced today the acquisition of INS1148, an investigational monoclonal antibody with the potential to be a first-in-class therapy to address respiratory and immunological and inflammatory diseases with high unmet need....Insmed plans to advance Phase 2 development programs for INS1148 initially in interstitial lung disease and moderate-to-severe asthma. INS1148 (formerly known as OpSCF) was developed by Opsidio, a private, clinical-stage company."

M&A • New P2 trial • Asthma • Immunology • Interstitial Lung Disease

Phase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - P2 | N=48 | Active, not recruiting | Sponsor: Opsidio, LLC | Recruiting ➔ Active, not recruiting

Enrollment closed • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Phase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - P2 | N=48 | Recruiting | Sponsor: Opsidio, LLC

Trial completion date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Opsidio Announces First Patient Dosed in Phase 2a Trial of OpSCF in Moderate to Severe Atopic Dermatitis (PRNewswire) - "Opsidio, LLC...announced the dosing of the first patient in the Phase 2a clinical trial of OpSCF, Opsidio's pioneering monoclonal antibody against stem cell factor, in patients suffering from moderate to severe atopic dermatitis....The currently enrolling OpSCF-201 study is a randomized, double-blind, placebo-controlled, Phase 2a study to evaluate the efficacy and safety of OpSCF in treating adults with moderate to severe atopic dermatitis. The primary endpoint is the percent change in the Eczema Area and Severity Index (EASI) score from baseline, at week 16."

Trial status • Atopic Dermatitis

Phase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - P2 | N=48 | Recruiting | Sponsor: Opsidio, LLC | Phase classification: P2a ➔ P2

Phase classification • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Phase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - P2a | N=48 | Recruiting | Sponsor: Opsidio, LLC | Not yet recruiting ➔ Recruiting

Enrollment open • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Phase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - P2a | N=48 | Not yet recruiting | Sponsor: Opsidio, LLC

New P2a trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology